AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
Go back to AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP| Aerosonic Corp. (NYSE: AIM) | Delayed: 0.38 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.38 | 52 Week High | $8.92 | |||
| Open | $0.38 | 52 Week Low | $2.64 | |||
| Day High | $0.39 | P/E | 0.61 | |||
| Day Low | $0.36 | EPS | $0.62 | |||
| Volume | 1,367,054 | |||||
